Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) CEO Dr Seth Lederman tells Proactive the clinical-stage biopharmaceutical company is developing a skin test to measure coronavirus exposure and T-cell immunity.
Dr Lederman says the group has received guidance from the FDA on the next steps and believes the group can advance to clinical studies by the second half of 2021.